Skip to main content

Table 2 Survival analysis of predicting CSS and OS after IPTW-adjusted by CRT or RT in NEEC patients

From: The survival impact of adjuvant radiotherapy and chemotherapy in patients with non-endometrioid endometrial carcinomas: a PSM-IPTW analysis based on SEER database

 

Cause-specific survival

Overall survival

Univariate analysis

Multivariate analysis

Univariate analysis

Multivariate analysis

Characteristics

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Adjuvant treatment

 CRT

Reference

   

Reference

   

 RT alone

0.94 (0.82–1.81)

0.384

1.48 (1.25–1.74)

 < 0.001

1.11 (0.98–1.26)

0.104

1.64 (1.42–1.89)

 < 0.001

Age group (years)

 < 50

Reference

   

Reference

   

 50–65

1.03 (0.70–1.49)

0.896

0.99 (0.68–1.46)

0.981

0.93 (0.65–1.34)

0.707

1.15 (0.80–1.65)

0.459

  > 65

1.29 (1.15–1.46)

 < 0.001

1.32 (0.90–1.94)

0.153

1.40 (1.26–1.56)

0.024

1.60 (1.11–2.30)

0.011

Year of diagnosis

 2004–2008

Reference

   

Reference

   

 2009–2013

0.90 (0.77–1.05)

0.164

0.91 (0.78–1.08)

0275

0.88 (0.76–1.01)

0.061

0.92 (0.80–1.07)

0.271

 2014–2018

0.85 (0.73–0.99)

0.036

0.87 (0.73–1.03)

0.114

0.82 (0.71–0.94)

0.005

0.87 (0.74–1.02)

0.093

Race redode

 Black

Reference

   

Reference

   

 Othersa

0.64 (0.49–0.83)

0.001

0.58 (0.45–0.76)

 < 0.001

0.71 (0.56–0.89)

0.004

0.69 (0.54–0.88)

0.002

 White

0.84 (0.73–0.97)

0.015

0.83 (0.71–0.96)

0.010

0.86 (0.75–0.97)

0.017

0.85 (0.75–0.98)

0.023

Marital status

 Divorced/separated

Reference

   

Reference

   

 Married

0.92 (0.77–1.10)

0.347

1.03 (0.85–1.23)

0.779

0.90 (0.76–1.06)

0.190

1.01 (0.85–1.19)

0.907

 Single/unmarried

0.94 (0.75–1.17)

0.557

0.92 (0.73–1.15)

0.462

0.95 (0.77–1.16)

0.588

0.95 (0.77–1.17)

0.620

 Unknown

0.81 (0.58–1.12)

0.197

0.77 (0.56–1.07)

0.125

0.85 (0.63–1.15)

0.292

0.82 (0.61–1.11)

0.202

 Widowed

1.21 (0.99–1.49)

0.067

1.16 (0.94–1.44)

0.169

1.34 (1.11–1.61)

0.002

1.24 (1.02–1.50)

0.030

Median household income

 < $50,000

Reference

   

Reference

   

 $50,000–65,000

1.07 (0.88–1.29)

0.495

1.09 (0.90–1.32)

0.371

1.11 (0.93–1.31)

0.241

1.05(0.89–1.25)

0.549

  > $65,000

0.80 (0.71–0.91)

0.001

0.93 (0.770–1.111)

0.405

0.79 (0.70–0.88)

 < 0.001

0.87 (0.74–1.03)

0.101

Grade

 I

Reference

   

Reference

   

 II

1.22 (0.61–2.45)

0.568

1.19 (0.59–2.39)

0.631

1.10 (0.63–1.91)

0.743

1.09 (0.62–1.90)

0.773

 III

1.79 (0.96–3.35)

0.067

1.67 (0.89–3.13)

0.112

1.33 (0.81–2.19)

0.256

1.30 (0.79–2.14)

0.310

 IV

1.73 (0.92–3.24)

0.089

1.55 (0.82–2.93)

0.176

1.32 (0.80–2.17)

0.282

1.24 (0.75–2.05)

0.412

 Unknown

1.44 (0.76–2.71)

0.259

1.35 (0.71–2.56)

0.358

1.10 (0.66–1.81)

0.724

1.07 (0.64–1.78)

0.797

Histology

 Clear cell

Reference

   

Reference

   

 Serous

1.36 (1.14–1.61)

 < 0.001

1.28 (1.07–1.53)

0.005

1.25 (1.08–1.45)

0.003

1.23(1.05–1.44)

0.009

 Carcinosarcoma

2.07 (1.63–2.61)

 < 0.001

2.01 (1.56–2.59)

 < 0.001

1.88 (1.52–2.33)

 < 0.001

1.87 (1.48–2.37)

 < 0.001

TNM stage

 T1N0M0

Reference

   

Reference

   

 T2N0M0

2.09 (1.69–2.59)

 < 0.001

1.95 (1.57–2.42)

 < 0.001

1.85 (1.53–2.23)

 < 0.001

1.72 (1.42–2.08)

 < 0.001

 T3-4aN0MO

3.21 (2.66–3.87)

 < 0.001

3.191 (2.63–3.88)

 < 0.001

2.70 (2.29–3.19)

 < 0.001

2.72 (2.29–3.23)

 < 0.001

 TanyN1M0

3.68 (3.12–4.33)

 < 0.001

3.86 (3.24–4.61)

 < 0.001

3.09 (2.68–3.57)

 < 0.001

3.41 (2.92–3.99)

 < 0.001

 TanyN2M0

4.94 (3.65–6.69)

 < 0.001

4.92 (3.59–6.74)

 < 0.001

3.88 (2.90–5.21)

 < 0.001

4.08 (3.01–5.52)

 < 0.001

 TanyNanyM1

8.82 (7.28–10.67)

 < 0.001

8.67 (7.03–10.68)

 < 0.001

6.94 (5.82–8.27)

 < 0.001

6.94 (5.73–8.41)

 < 0.001

Surgery mode

 Total hysterectomy

Reference

   

Reference

   

 Extended hysterectomy

1.37 (1.14–1.64)

0.001

1.05 (0.87–1.26)

0.635

1.26 (1.07–1.50)

0.007

0.99 (0.83–1.18)

0.895

Lymphadenectomy

 Yes

Reference

   

Reference

   

 No

1.60 (1.37–1.87)

 < 0.001

1.34 (1.13–1.58)

 < 0.001

1.73 (1.50–1.99)

 < 0.001

1.46 (1.25–1.70)

 < 0.001

 SLN biopsy/removed

0.91 (0.67–1.23)

0.519

0.975 (0.716–1.327)

0.871

0.89 (0.67–1.18)

0.414

0.94 (0.70–1.26)

0.685

Tumor Size (mm)

 < 20

Reference

   

Reference

   

 20–39

1.40 (1.10–1.77)

0.006

1.14 (0.89–1.45)

0.291

1.41 (1.13–1.75)

0.002

1.19 (0.96–1.48)

0.122

 40–59

2.09 (1.65–2.64)

 < 0.001

1.42 (1.12–1.81)

0.003

1.99 (1.61–2.47)

 < 0.001

1.43 (1.15–1.78)

0.001

 60–79

2.34 (1.80–3.03)

 < 0.001

1.34 (1.02–1.74)

0.033

2.35 (1.86–2.98)

 < 0.001

1.42 (1.11–1.80)

0.005

  ≥ 80

3.31 (2.57–4.26)

 < 0.001

1.74 (1.34–2.26)

 < 0.001

3.29 (2.61–4.15)

 < 0.001

1.87 (1.47–2.37)

 < 0.001

 Unknown

1.62 (1.28–2.04)

 < 0.001

1.24 (0.98–1.57)

0.076

1.65 (1.34–2.04)

 < 0.001

1.31 (1.06–1.62)

0.014

  1. RT radiotherapy, CRT chemoradiotherapy, SLN sentinel lymph node. Race Othersa: American Indian, Asian/Pacific Islander. IPTW inverse probability treatment weighting